Patents Assigned to Medarex, Inc.
  • Peptidyl prodrugs and linkers and stabilizers useful therefor
    Patent number: 7977465
    Abstract: The present invention provides analogues of duocarmycins that are potent cytotoxins. Also provided are peptidyl and disulfide linkers that are cleaved in vivo. The linkers are of use in forming prodrugs and conjugates of the cytotoxins of the invention as well as other diagnostic and therapeutic moieties. The invention provides prodrugs and conjugates of the duocarmycin analogues with the linker arms of the invention.
    Type: Grant
    Filed: March 4, 2009
    Date of Patent: July 12, 2011
    Assignee: Medarex, Inc.
    Inventors: Howard P. Ng, Danny P. C. McGee, Guoxian Wu, Jimmie Moore, Zhi-Hong Li, Sanjeev Gangwar, Oliver L. Saunders, Irina Astafieva
  • METHODS FOR THE THERAPY OF INFLAMMATORY BOWEL DISEASE USING A TYPE-1 INTERFERON ANTAGONIST
    Publication number: 20110165158
    Abstract: Compositions and methods for the therapy of Inflammatory Bowel Disease (IBD), including Celiac Disease, Crohn's Disease, and Ulcerative Colitis, are disclosed. Illustrative compositions comprise one or more anti-type 1 interferon antagonists, such as anti-type 1 interferon receptor antibody antagonists and fragments thereof, as well as polypeptides and small molecules that inhibit the interaction of type 1 interferon with its receptor (IFNAR).
    Type: Application
    Filed: March 17, 2011
    Publication date: July 7, 2011
    Applicant: MEDAREX, INC.
    Inventors: Lesley B. Pickford, Christopher R. Bebbington, Geoffrey T. Yarranton, David King
  • Cytotoxic compounds and conjugates
    Patent number: 7968586
    Abstract: The present disclosure provides cytoxic compounds useful as drugs or prodrugs and to drug-cleavable substrate conjugates where the drug and cleavable substrate are optionally linked through a self-immolative linker.
    Type: Grant
    Filed: November 9, 2006
    Date of Patent: June 28, 2011
    Assignee: Medarex, Inc.
    Inventors: Sanjeev Gangwar, Bilal Sufi
  • USE OF AN EFFICACY MARKER FOR OPTIMIZING THERAPEUTIC EFFICACY OF AN ANTI-HUMAN PD-1 ANTIBODY ON CANCERS
    Publication number: 20110123550
    Abstract: A purpose of the present invention is to provide a method capable of more effectively prescribing an anti-human PD-1 antibody for anti-cancer therapy, a method for estimating or optimizing therapeutic efficacy thereof, and further an efficacy marker that can be used in methods thereof. The present invention enables selection of the cancer patient in whom the therapeutic efficacy of the anti-human PD-1 antibody can be expected in future, by measuring the change which is more than a certain level of several kinds of efficacy markers in blood after administering the initial dose or doses of the anti-human PD-1 antibody compared to that prior to administering the initial dose, and provides a new prescription of the anti-human PD-1 antibody for anti-cancer therapy.
    Type: Application
    Filed: July 3, 2009
    Publication date: May 26, 2011
    Applicants: ONO PHARMACEUTICAL CO., LTD., MEDAREX, INC.
    Inventors: Shiro Shibayama, Takao Yoshida, Tamon Hayashi, Akio Hayashi, Jun Murai
  • Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
    Patent number: 7943743
    Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-L1 antibodies.
    Type: Grant
    Filed: June 30, 2006
    Date of Patent: May 17, 2011
    Assignee: Medarex, Inc.
    Inventors: Alan J. Korman, Mark J. Selby, Changyu Wang, Mohan Srinivasan, David B. Passmore, Haichun Huang, Haibin Chen
  • Methods for the therapy of Inflammatory Bowel Disease using a type-1 interferon antagonist
    Patent number: 7939076
    Abstract: Compositions and methods for the therapy of Inflammatory Bowel Disease (IBD), including Celiac Disease, Crohn's Disease, and Ulcerative Colitis, are disclosed. Illustrative compositions comprise one or more anti-type 1 interferon antagonists, such as anti-type 1 interferon receptor antibody antagonists and fragments thereof, as well as polypeptides and small molecules that inhibit the interaction of type 1 interferon with its receptor (IFNAR).
    Type: Grant
    Filed: April 23, 2004
    Date of Patent: May 10, 2011
    Assignee: Medarex, Inc.
    Inventors: Lesley B. Pickford, Christopher R. Bebbington, Geoffrey T. Yarranton, David King
  • Human Anti-NGF Neutralizing Antibodies as Selective NGF Pathway Inhibitors
    Publication number: 20110091476
    Abstract: This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.
    Type: Application
    Filed: September 13, 2010
    Publication date: April 21, 2011
    Applicants: AMGEN INC., MEDAREX, INC.
    Inventors: Kenneth D. Wild, JR., James J.S. Treanor, Haichun Huang, Heather Inoue, Tie J. Zhang, Frank Martin
  • Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
    Patent number: 7910798
    Abstract: The invention provides transgene constructs for expressing chimeric antibodies, and transgenic non-human host animals carrying such constructs, wherein the chimeric antibodies comprise human variable regions and constant regions of the non-human transgenic host animal. The presence of immunoglobulin constant regions of the host animal allows for generation of improved antibodies in such transgenic host animals. Subsequently, the chimeric antibodies can be readily converted to fully human antibodies using recombinant DNA techniques. Thus, the invention provides compositions and methods for generating human antibodies in which chimeric antibodies raised in vivo in transgenic mice are used as intermediates and then converted to fully human antibodies in vitro.
    Type: Grant
    Filed: March 30, 2007
    Date of Patent: March 22, 2011
    Assignee: Medarex, Inc.
    Inventors: Dawn M. Tanamachi, Peter Brams, Amelia Black
  • Prodrugs activated by plasmin and their use in cancer chemotherapy
    Patent number: 7893023
    Abstract: The product of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide having a plasmin peptide substrate of 2-4 amino acids and mono- or di-peptide linkage, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by plasmin. Also disclosed are methods of making and using the prodrug compounds.
    Type: Grant
    Filed: June 11, 2008
    Date of Patent: February 22, 2011
    Assignee: Medarex, Inc.
    Inventors: Andre Trouet, Vincent Dubois, Alexandre Passioukov
  • Human Anti-NGF Neutralizing Antibodies as Selective NGF Pathway Inhibitors
    Publication number: 20110040076
    Abstract: This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.
    Type: Application
    Filed: August 18, 2010
    Publication date: February 17, 2011
    Applicants: AMGEN INC., MEDAREX, INC.
    Inventors: Kenneth D. Wild, JR., James J.S. Treanor, Haichun Huang, Heather Inoue, Tie J. Zhang, Frank Martin
  • Humanized antibodies to interferon alpha receptor-1 (IFNAR-1)
    Patent number: 7888484
    Abstract: Humanized monoclonal antibodies which bind to IFNAR-1, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the humanized antibodies and therapeutic and diagnostic methods for using the humanized antibodies.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: February 15, 2011
    Assignee: Medarex, Inc.
    Inventors: Josephine M. Cardarelli, Tseng-hui Timothy Chen, David King, Christopher R. Bebbington, Sarah Lee Pogue, Francis J. Carr, Stephen Williams
  • ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF
    Publication number: 20110027274
    Abstract: Antiproliferative compounds having a structure represented by formula (II), where n, R1, R2, R3, R4, and R5 are as defined herein, can be used to treat tumors, optionally when conjugated to a ligand such as an antibody:
    Type: Application
    Filed: July 29, 2010
    Publication date: February 3, 2011
    Applicant: Medarex, Inc.
    Inventors: Heng Cheng, Qiang Cong, Sanjeev Gangwar, Qian Zhang
  • MONOCLONAL ANTIBODIES AGAINST PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LACKING IN FUCOSYL RESIDUES
    Publication number: 20110028696
    Abstract: The invention pertains to anti-PSMA antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity as compared to the fucosylated form of the antibodies. The invention also provides host cells that express the anti-PSMA antibodies that lack fucosyl residues, wherein the host cells are deficient for a fucosyl transferase. Methods of using the antibodies to inhibit the growth of PSMA+ cells, such as tumor cells, are also provided.
    Type: Application
    Filed: October 13, 2010
    Publication date: February 3, 2011
    Applicant: MEDAREX, INC.
    Inventors: Josephine M. CARDARELLI, David B. PASSMORE, Jenny ALBANESE, Lei ZHU
  • Monoclonal antibodies against prostate specific membrane antigen (PSMA) lacking in fucosyl residues
    Patent number: 7875278
    Abstract: The invention pertains to anti-PSMA antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity as compared to the fucosylated form of the antibodies. The invention also provides host cells that express the anti-PSMA antibodies that lack fucosyl residues, wherein the host cells are deficient for a fucosyl transferase. Methods of using the antibodies to inhibit the growth of PSMA+ cells, such as tumor cells, are also provided.
    Type: Grant
    Filed: February 17, 2006
    Date of Patent: January 25, 2011
    Assignee: Medarex, Inc.
    Inventors: Josephine M. Cardarelli, David B. Passmore, Jenny Albanese, Lei Zhu
  • Human anti-B7RP1 neutralizing antibodies
    Patent number: 7868140
    Abstract: This invention provides antibodies that interact with or bind to human B7 related protein-1 (B7RP1) and antibodies that bind to and neutralize the function of B7RP1 thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing B7RP1 function, and particularly for treating immune disorders (e.g., inappropriate immune response) by administering a pharmaceutically effective amount of anti-B7RP1 antibodies. Methods of detecting the amount of B7RP1 in a sample using anti-B7RP1 antibodies are also provided.
    Type: Grant
    Filed: July 18, 2006
    Date of Patent: January 11, 2011
    Assignees: Amgen Inc., Medarex Inc.
    Inventors: Gerald Siu, Wenyan Shen, Steven Kiyoshi Yoshinaga, Haichun Huang
  • Transgenic Trasnchromosomal Rodents for Making Human Antibodies
    Publication number: 20110003319
    Abstract: The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.
    Type: Application
    Filed: September 9, 2010
    Publication date: January 6, 2011
    Applicants: KYOWA HAKKO KIRIN CO., LTD., MEDAREX, INC.
    Inventors: KAZUMA TOMIZUKA, ISAO ISHIDA, NILS LONBERG, EDWARD L. HALK
  • Human monoclonal antibodies against CD30
    Publication number: 20100322920
    Abstract: Isolated human monoclonal antibodies which bind to CD30 (e.g., human CD30) are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are derivatives of the human antibodies (e.g., bispecific antibodies and immunoconjugates), pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Application
    Filed: April 4, 2008
    Publication date: December 23, 2010
    Applicant: MEDAREX, INC.
    Inventors: Tibor Keler, Robert Graziano, John Treml, Yashwant M. Deo
  • Methods and compounds for preparing CC-1065 analogs
    Patent number: 7847105
    Abstract: A method of forming a CBI CC-1065 analog utilizes NH2 as a starting material, where R3 is H or alkyl and R6 is H, substituted or unsubstituted lower alkyl, cyano, or alkoxy. Intermediates (I) are used and are claimed.
    Type: Grant
    Filed: October 18, 2006
    Date of Patent: December 7, 2010
    Assignee: Medarex, Inc.
    Inventors: Sanjeev Gangwar, Qian Zhang
  • Methods for characterizing glycosylation sites
    Patent number: 7820399
    Abstract: The present invention provides methods for isolating and characterizing the glycosylation sites of a glycoprotein, such as a glycosylated antibody. In particular, the methods employ affinity capture, liquid chromatography, and mass spectrometry to determine, for example, the location of the glycopeptide, the heterogeneity of the glycan attached to the glycopeptide, the mass of the glycopeptide, and/or the peptide sequence.
    Type: Grant
    Filed: May 16, 2008
    Date of Patent: October 26, 2010
    Assignee: Medarex, Inc.
    Inventors: Zhigang Wu, Mohan Srinivasan
  • Tripeptide prodrug compounds
    Patent number: 7816317
    Abstract: The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide of three amino acids, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by a trouase enzyme such as Thimet oligopeptidase. Also disclosed are methods of making and using the prodrug compounds.
    Type: Grant
    Filed: March 27, 2007
    Date of Patent: October 19, 2010
    Assignee: Medarex, Inc.
    Inventors: Christopher R. Bebbington, Vincent Dubois, Sanjeev Gangwar, Thomas J. Lobl, Matthew H. Nieder, Lesley B. Pickford, Andre Trouet, Geoffrey T. Yarranton